Ghadban Tarik, Reeh Matthias, Koenig Alexandra M, Nentwich Michael F, Bellon Eugen, Izbicki Jakob R, Vashist Yogesh K, Kutup Asad
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ann Surg. 2017 Dec;266(6):988-994. doi: 10.1097/SLA.0000000000001995.
The aim of this study is to investigate the impact of the circumferential resection margin (CRM) in esophageal cancer on survival and recurrence in patients without pretreatment.
Whereas the infiltration of the proximal or distal resection margin is associated with poor survival and higher recurrence, studies looking at the role of the circumferential resection margin on survival and local recurrence after esophagectomy are conflicting.
Influence of CRM infiltration according to the College of American Pathologists (CAP) and Royal College of Pathologists (RCP) on long-term survival of 180 patients with resected pT3 tumors and without neoadjuvant therapy was analyzed.
A positive CRM was found in 76 (42.4%) patients according to RCP and 44 (24.4%) patients according to CAP. The CRM status had neither according to CAP nor according to RCP a significant impact on overall survival (P = 0.317 and 0.655, respectively), local recurrence (P = 0.716 and 0.900, respectively), or distant tumor relapse (P = 0.303 and 0.471, respectively).Lymphatic tumor spread found in 129 (71.7%) patients was an independent prognosticator (P = 0.002). In 137 (76.1%) patients who had a transthoracic esophagectomy a CRM infiltration was significantly lower according to CAP compared with 43 (23.9%) patients who had a transhiatal esophagectomy (P = 0.026).
CRM was found to have no impact on survival and recurrence in esophageal cancer. Therefore, the possible impact of neoadjuvant pretreatment in locally advanced tumors should be considered with caution in terms of an improved resectability.
本研究旨在探讨食管癌环周切缘(CRM)对未经预处理患者生存及复发的影响。
尽管近端或远端切缘浸润与生存率低及复发率高相关,但关于食管切除术后环周切缘对生存及局部复发作用的研究结果相互矛盾。
分析美国病理学家学会(CAP)和皇家病理学家学会(RCP)定义的CRM浸润对180例接受pT3肿瘤切除且未接受新辅助治疗患者长期生存的影响。
根据RCP,76例(42.4%)患者CRM阳性;根据CAP,44例(24.4%)患者CRM阳性。CRM状态无论依据CAP还是RCP,对总生存(分别为P = 0.317和0.655)、局部复发(分别为P = 0.716和0.900)或远处肿瘤复发(分别为P = 0.303和0.471)均无显著影响。129例(71.7%)患者出现的肿瘤淋巴转移是独立预后因素(P = 0.002)。在137例(76.1%)接受经胸食管切除术的患者中,依据CAP,CRM浸润显著低于43例(23.9%)接受经裂孔食管切除术的患者(P = 0.026)。
发现CRM对食管癌的生存及复发无影响。因此,对于局部晚期肿瘤,在考虑新辅助预处理对提高切除率可能产生的影响时应谨慎。